Maintenance of statin use over 3 years following acute coronary syndromes: A national data linkage study (ANZACS-QI-2)

Heart

Volumn 100, Issue 10, 2014, Pages 770-774

  Grey, Corina ^a   Jackson, Rod ^a   Wells, Sue ^a   Thornley, Simon ^a   Marshall, Roger ^a   Crengle, Sue ^b   Harrison, Jeff ^a   Riddell, Tania ^a   Kerr, Andrew ^a,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^c MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG USE; ETHNICITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION POSSESSION RATIO; NEW ZEALAND; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HOSPITALS, PUBLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEW ZEALAND; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84899633614     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304960     Document Type: Article

References (29)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;339:1349-57.
3. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly postmyocardial infarction patients.Pharmacoepidemiol Drug Saf 2008;17:1189-96.
4. Chodick G, Shlev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-79.
5. Jackevicius CA, Li P, Tu JV. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008;117:1028-36.
6. Thornley S, Marshall R, Chan WC, et al. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event. Eur J Prev Cardiol 2012;19:349-57.
7. Ministry of Health. National Health Index data dictionary (version 5.3). Ministry of Health, 2009.
8. Chan WC, Wright C, Tobias M, et al. Explaining trends in coronary heart disease hospitalisations in New Zealand: trend for admissions and incidence can be in opposite directions. Heart 2008;94:1589-93.
9. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74. (Pubitemid 44336271)
10. Salmond C, Crampton P. NZ Dep 2001 Index of Deprivation. User's Manual.Wellington: Wellington School of Medicine and Health Sciences, 2002.
11. Thornley S, Wright C, Marshall R, et al. Can the prevalence of diagnosed diabetes be estimated from linked national health records? The validity of a method applied in New Zealand. J Prim Health Care 2011;3:262-8.
12. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003;3:21.
13. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-6.
14. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009.
15. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7. (Pubitemid 34787477)
16. Shah ND, Dunlay SM, Ting HH, et al. Long-term medication adherence after myocardial infarction: experience of a community. Am J Med 2009; 122:961.e7-13.
17. Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010; 103:363-75.
18. Kirchmayer U, Agabitis N, Belleudi V, et al. Socio-demographic differences in adherence to evidence-based drug therapy after discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy. J Clin Pharm Ther 2012;37:37-44.
19. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-8.
20. Hudson M, Richard H, Pilote L. Parabolas of medication use and discontinuation after myocardial infarction-are we closing the treatment gap? Pharmacoepidemiol Drug Saf 2007;16:773-85. (Pubitemid 47180366)
21. Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother 2010;44:1410-21.
22. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008;(2):CD000011.
23. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-45.
24. Esposti LD, Saragoni S, Batacchi P, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther 2012;34:190-9.
25. Benner J, Glynn R, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61. (Pubitemid 34787476)
26. Mann DM, Allegranate JP, Natarajan S, et al. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007;21:311-16. (Pubitemid 47387472)
27. Tukuitonga C, Bindman A. Ethnic and gender differences in the use of coronary artery revascularisation procedures in New Zealand. N Z Med J 2002;115.
28. Peeters A, Manmun AA, Willekens F, et al. A cardiovascular life history-a life course analysis of the original Framingham Heart Study cohort. Eur Heart J 2002;23:458-66. (Pubitemid 35204185)
29. Bramley D, Hebert P, Jackson R, et al. Indigenous disparities in disease-specific mortality, a cross-country comparison: New Zealand, Australia, Canada and the United States. N Z Med J 2004;117:1207.